.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EL04_Orelabrutinib.Orelabrutinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EL04_Orelabrutinib.Orelabrutinib| name: | Orelabrutinib |
| ATC code: | L01EL04 | route: | oral |
| n-compartments | 1 |
Orelabrutinib is an orally administered, potent, and highly selective Bruton tyrosine kinase (BTK) inhibitor developed primarily for the treatment of B-cell malignancies such as chronic lymphocytic leukemia and mantle cell lymphoma. It is approved for clinical use in China and is under investigation in other regions.
Pharmacokinetic parameters as reported in adult patients with B-cell malignancies after oral administration.